Skip to content

Biomarkers of Injectable Extended Release Naltrexone Treatment

Biomarkers of Disease and Response to Treatment in Opioid Addiction

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02324725
Enrollment
32
Registered
2014-12-24
Start date
2011-10-31
Completion date
2021-12-31
Last updated
2023-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heroin Dependence, Opioid Dependence

Keywords

naltrexone, neuroimaging, heroin, addiction, dependence, opioid, Vivitrol®, functional magnetic resonance imaging

Brief summary

This study evaluates the biological markers of treatment of opioid dependent individuals with an extended release formulation of the opioid antagonist naltrexone. The biological measures include functional MRI, blood levels of naltrexone and its metabolites, urine toxicology and behavioral tests probing various aspects of personality, memory, reward processing and attention.

Detailed description

This study is using blood oxygenation level dependent (BOLD) functional magnetic resonance imaging (fMRI) to examine the brain predictors of adherence and outcomes of opioid antagonist therapy. Opioid-dependent intravenous heroin users are offered up to 3 monthly injections of the extended-release naltrexone (XRNTX) contingent upon successful outpatient non-opioid detoxification, with an additional 4 weeks of follow up. Brain responses to heroin-related pictures are recorded using fMRI prior to the 1st XRNTX injection and approximately 2 weeks thereafter the 1st XRNTX injection. Primary clinical variables include the number of injections (maximum of 3) accepted by participants, change in self-reported craving for opioids after exposure to drug-related visual cues during the brain fMRI sessions, urine levels of ten commonly abused substances and self-report of cigarette use.

Interventions

DRUGNaltrexone

Up to three monthly injections of 380 mg of naltrexone suspended in dissolvable polymer microspheres and administered intramuscularly

Sponsors

University of Pennsylvania
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
No

Inclusion criteria

1. DSM-IV-TR diagnosis of opioid dependence, active opioid use, confirmed by urine toxicology screen and self-reported monthly intravenous heroin use for more than 2 weeks in the past 3 months 2. urine toxicology screen negative for opioids after detoxification 3. good physical health as indicated by history and physical examination, screening blood work-up and urinalysis.

Exclusion criteria

1. chronic medical illnesses; 2. current use of medications potentially confounding brain activity, such as anti-dopaminergic agents, anti-depressants and beta-blockers; 3. current DSM-IV-TR Axis I psychiatric disorders other than opioid and nicotine dependence; 4. life time history of concurrent IV cocaine and heroin (speedball) administration; 5. pregnancy or breastfeeding; 6. history of clinically significant head trauma; 7. contraindications for naltrexone treatment including medical conditions requiring opioid analgesics, e.g. chronic pain or planned surgery, obesity, elevated liver enzymes (\> 3 times upper limit of normal), failure to complete opioid detoxification 8. contraindications for MRI, i.e. indwelling magnetically active foreign bodies and phobia to enclosed spaces

Design outcomes

Primary

MeasureTime frameDescription
Brain response to heroin-related visual cues1 hourBrain, behavioral and motivational (e.g. craving) response to audiovisual drug-related and control stimuli (images, smells and sounds) and to standard tasks of decision making, self-appraisal, response inhibition, social interaction and reward processing.

Secondary

MeasureTime frameDescription
Cigarettes smoked per day6 monthsbehavioral
Urine toxicology6 monthsUrine toxicology for methamphetamine, amphetamines, cannabis, cocaine, oxycodone, buprenophine, methadone, opioids, benzodiazepines and barbiturates.
Injections3 monthsNumber of injections (maximum of 3) accepted by participants
Motivational response to opioid-related visual cues measured by self-reported craving for opioids2 hoursChange in self-reported craving for opioids after exposure to opioid-related visual cues during functional MRI sessions

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 18, 2026